Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Saizeng Medical Licenses TSHR Antibody to Yarrow for $1.4B in Graves’ Disease Deal

Fineline Cube Dec 16, 2025
Company Deals

uBriGene Partners with Circurna on circRNA Manufacturing for Global Trials

Fineline Cube Dec 16, 2025
Company Deals

Dren Bio, Sanofi Forge $1.8B B‑Cell Therapy Deal with US Co‑Promote Option

Fineline Cube Dec 16, 2025
Company Deals

Adaptive Licenses TCR Data to Pfizer in $890M Deal for Rheumatoid Arthritis

Fineline Cube Dec 16, 2025
Company Deals

Sobi Acquires Arthrosi for $1.5 Billion to Add Gout Drug to Portfolio

Fineline Cube Dec 15, 2025
Policy / Regulatory

FDA Removes Key RWE Limitation, Allowing Drug and Device Submissions Without Individual Patient Data

Fineline Cube Dec 16, 2025
Company Drug

Orelabrutinib First BTK Inhibitor to Hit Phase 3 in Lupus as InnoCare NMPA Filing Cleared

Fineline Cube Dec 16, 2025
Company Drug

ENHERTU Wins FDA Approval as First-Line HER2 Breast Cancer Therapy

Fineline Cube Dec 16, 2025
Company Deals

Meihua Medtech Secures Over RMB 100M in Series B Financing Led by Eight Roads and Sunland

Fineline Cube Dec 19, 2022

China’s Zhuhai Meihua Medical Technology Co., Ltd, a leading clinical microbiology laboratory overall solutions provider,...

Company Deals

InnerMedical Secures RMB 300M in Series D Funding Led by Green Pine and Simiao

Fineline Cube Dec 19, 2022

InnerMedical Co., Ltd, a leading chronic disease diagnosis and treatment solutions provider based in Shenzhen,...

Company

Novartis China Establishes Health Development Fund in Boao Lecheng

Fineline Cube Dec 19, 2022

Novartis (NYSE: NVS) China has announced the establishment of a health development fund, a significant...

Company Drug

Henlius’ Serplulimab Receives Orphan Drug Designation in Europe for SCLC

Fineline Cube Dec 16, 2022

Shanghai Henlius Biotech (HKG: 2696) has announced receiving orphan drug designation (ODD) status from the...

Company Deals

XingImaging and Mitro Biotech Partner for Contract Research Services in China

Fineline Cube Dec 16, 2022

US-based XingImaging LLC and China-based Mitro Biotech Co., Ltd have announced a partnership to provide...

Company Drug

Doer Bio and MSD Collaborate on Clinical Trial for Anti-Claudin18.2 Antibody DR30303

Fineline Cube Dec 16, 2022

China-based Zhejiang Doer Biologics Co., Ltd has announced a clinical trial collaboration agreement with US...

Company Policy / Regulatory

WuXi Biologics’ Shanghai Subsidiary Removed from US UVL

Fineline Cube Dec 16, 2022

China-based Contract Research, Development and Manufacturing Organization (CRDMO) WuXi Biologics (HKG: 2269) announced that its...

Policy / Regulatory

Liaoning Publishes Fourth Round of Volume-Based Procurement Winning Bids

Fineline Cube Dec 16, 2022

The Liaoning drug and medical consumables centralized procurement website has published the fourth round of...

Company Deals

Cryofocus Medtech Set for IPO on Hong Kong Stock Exchange

Fineline Cube Dec 16, 2022

China-based Cryofocus Medtech (Shanghai) Co., Ltd, a minimally invasive interventional cryotherapy device maker, is set...

Company Medical Device

NMPA Approves SonoScape and Acoustic Life’s Intravascular Ultrasound Products

Fineline Cube Dec 16, 2022

The National Medical Products Administration (NMPA) has approved Chinese firms SonoScape Medical Corp’s intravascular ultrasound...

Company Drug

Boehringer Ingelheim’s Spevigo Approved by NMPA for Generalized Pustular Psoriasis

Fineline Cube Dec 15, 2022

German giant Boehringer Ingelheim announced receiving marketing approval from the National Medical Products Administration (NMPA)...

Drug

Cosmo Pharmaceuticals’ Lumeblue Completes Phase III Trial in China

Fineline Cube Dec 15, 2022

Ireland-based Cosmo Pharmaceuticals N.V. (OTCMKTS: CMOPF) revealed that its Lumeblue (methylthioninium chloride) diagnostic agent has...

Company Medical Device

Acotec Scientific’s NEO-Skater Balloon Approved by NMPA for Intracranial Vessels

Fineline Cube Dec 15, 2022

China-based Acotec Scientific Holdings Ltd (HKG: 6669) has announced receiving market approval from the National...

Company Drug

Tracon Pharmaceuticals Provides Positive Update on Envafolimab Phase II Trial

Fineline Cube Dec 15, 2022

China-based Alphamab Oncology (HKG: 9966)’s US partner Tracon Pharmaceuticals (NASDAQ: TCON) has provided an early...

Company Drug

Sirnaomics Announces Interim Results for STP705 in Phase IIb Study for isSCC

Fineline Cube Dec 15, 2022

Sino-US siRNA therapy developer Sirnaomics Ltd (HKG: 2257) has announced the interim results of part...

Company Drug

Henlius Biotech Initiates Phase I Trial for HLX60 in Australia

Fineline Cube Dec 15, 2022

Shanghai Henlius Biotech, Inc. (HKG: 2696) has announced the first subject dosed in a Phase...

Company Deals

China Meheco to Import and Distribute Pfizer’s Paxlovid in Mainland China

Fineline Cube Dec 15, 2022

China Meheco Group Co., Ltd (SHA: 600056) has announced an agreement with US major Pfizer...

Company Medical Device

Zylox-Tonbridge Receives NMPA Approval for ZYLOX Octoplus Vena Cava Filter

Fineline Cube Dec 15, 2022

China-based nerve and peripheral vascular interventional device developer Zylox-Tonbridge Medical Technology (HKG: 2190) has announced...

Company Deals

Innovent Biologics Collaborates with LG Chem for Tigulixostat in China

Fineline Cube Dec 15, 2022

China-based Innovent Biologics (HKG: 1801) has announced a strategic collaboration and license agreement with South...

Deals Drug

Everest Medicines Achieves Preclinical Milestone for mRNA Rabies Vaccine

Fineline Cube Dec 15, 2022

China-based Everest Medicines (HKG: 1952) has announced that the company has achieved the preclinical proof-of-concept...

Posts pagination

1 … 518 519 520 … 598

Recent updates

  • Orelabrutinib First BTK Inhibitor to Hit Phase 3 in Lupus as InnoCare NMPA Filing Cleared
  • Saizeng Medical Licenses TSHR Antibody to Yarrow for $1.4B in Graves’ Disease Deal
  • Zhicheng’s TAVR Robotic System Enters NMPA Innovation Pathway
  • ENHERTU Wins FDA Approval as First-Line HER2 Breast Cancer Therapy
  • FDA Removes Key RWE Limitation, Allowing Drug and Device Submissions Without Individual Patient Data
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Drug

Orelabrutinib First BTK Inhibitor to Hit Phase 3 in Lupus as InnoCare NMPA Filing Cleared

Company Deals

Saizeng Medical Licenses TSHR Antibody to Yarrow for $1.4B in Graves’ Disease Deal

Company Medical Device

Zhicheng’s TAVR Robotic System Enters NMPA Innovation Pathway

Company Drug

ENHERTU Wins FDA Approval as First-Line HER2 Breast Cancer Therapy

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.